Mycophenolate mofetil: Selective T cell inhibition
Mycophenolate mofetil: Selective T cell inhibition
复制标题
DOI：
10.1097/00000441-200204000-00005
复制
发表时间：
2002-04-01
影响因子：
3.1
通讯作者：
Harisdangkul, V
中科院分区：
文献类型：
--
作者：
McMurray, RW;Harisdangkul, V
霉酚酸酯是T细胞增殖和粘附的抑制剂。其主要作用模式是抑制肌苷一磷酸脱氢酶，这是T淋巴细胞所需的嘌呤补救途径。虽然T细胞在类风湿性关节炎（RA）中的作用一直存在争议，但霉酚酸酯在RA患者中成功使用的初步报告清楚地表明，其有效特性需要进一步研究。其有利的风险/受益比，广泛的临床经验，在肾移植，其最近扩展到其他风湿性疾病表明，这种新的抗风湿剂具有显着的治疗潜力，抑制滑膜炎症。
Mycphenolate mofetil is a suppressor of T cell proliferation and adhesion. Its primary mode of action is inhibition of inosine monophosphate dehydrogenase, a purine salvage pathway required by T lymphocytes. Although the role of T cells in rheumatoid arthritis (RA) has been controversial, a preliminary report of mycophenolate mofetil's successful use in RA patients clearly suggests that its efficacious properties need further investigation. Its favorable risk/benefit ratio, a broad clinical experience in kidney transplantation, and its recent extension to other rheumatic diseases suggests that this new antiheumatic agent has significant therapeutic potential for suppression of synovial inflammation.